GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Cyclically Adjusted Book per Share

IRLAB Therapeutics AB (OSTO:IRLAB A) Cyclically Adjusted Book per Share : kr5.41 (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

IRLAB Therapeutics AB's adjusted book value per share for the three months ended in Mar. 2025 was kr0.089. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr5.41 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2025-06-03), IRLAB Therapeutics AB's current stock price is kr7.10. IRLAB Therapeutics AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was kr5.41. IRLAB Therapeutics AB's Cyclically Adjusted PB Ratio of today is 1.31.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of IRLAB Therapeutics AB was 1.36. The lowest was 1.27. And the median was 1.32.


IRLAB Therapeutics AB Cyclically Adjusted Book per Share Historical Data

The historical data trend for IRLAB Therapeutics AB's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Cyclically Adjusted Book per Share Chart

IRLAB Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

IRLAB Therapeutics AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 5.41

Competitive Comparison of IRLAB Therapeutics AB's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, IRLAB Therapeutics AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRLAB Therapeutics AB's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Cyclically Adjusted PB Ratio falls into.


;
;

IRLAB Therapeutics AB Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, IRLAB Therapeutics AB's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.089/132.8245*132.8245
=0.089

Current CPI (Mar. 2025) = 132.8245.

IRLAB Therapeutics AB Quarterly Data

Book Value per Share CPI Adj_Book
201312 0.000 100.541 0.000
201412 2.071 100.225 2.745
201512 3.770 100.276 4.994
201603 0.000 100.751 0.000
201606 0.000 101.019 0.000
201609 0.000 101.138 0.000
201612 4.027 102.022 5.243
201703 5.596 102.022 7.286
201706 5.298 102.752 6.849
201709 4.717 103.279 6.066
201712 4.352 103.793 5.569
201803 3.907 103.962 4.992
201806 5.991 104.875 7.588
201809 5.607 105.679 7.047
201812 5.155 105.912 6.465
201903 4.725 105.886 5.927
201906 3.986 106.742 4.960
201909 3.463 107.214 4.290
201912 4.145 107.766 5.109
202003 6.152 106.563 7.668
202006 5.608 107.498 6.929
202009 5.033 107.635 6.211
202012 7.173 108.296 8.798
202103 6.335 108.360 7.765
202106 5.821 108.928 7.098
202109 8.179 110.338 9.846
202112 7.720 112.486 9.116
202203 7.139 114.825 8.258
202206 6.632 118.384 7.441
202209 6.247 122.296 6.785
202212 5.607 126.365 5.894
202303 4.459 127.042 4.662
202306 3.593 129.407 3.688
202309 2.853 130.224 2.910
202312 2.232 131.912 2.247
202403 1.480 132.205 1.487
202406 1.344 132.716 1.345
202409 0.733 132.304 0.736
202412 0.629 132.987 0.628
202503 0.089 132.825 0.089

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


IRLAB Therapeutics AB  (OSTO:IRLAB A) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

IRLAB Therapeutics AB's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=7.10/5.41
=1.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of IRLAB Therapeutics AB was 1.36. The lowest was 1.27. And the median was 1.32.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


IRLAB Therapeutics AB Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


IRLAB Therapeutics AB Business Description

Industry
Traded in Other Exchanges
N/A
Address
Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB Headlines

No Headlines